TRP_1170x120_3-8-19

Mylan N.V.

Launch of generic Lialda expands Mylan’s gastroenterology product offering

Launch of generic Lialda expands Mylan’s gastroenterology product offering

PITTSBURGH — Mylan N.V. announced the U.S. launch of mesalamine delayed-release tablets USP, 1.2 g, a generic version of Shire’s Lialda Delayed-Release Tablets. Mylan Pharmaceuticals received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the induction of remission in patients with active,

Mylan launches first generic for Adcirca tablets

Mylan launches first generic for Adcirca tablets

HERTFORDSHIRE, England and PITTSBURGH — Mylan N.V. announced the U.S. launch of tadalafil tablets USP, 20 mg, the first generic version of the reference listed drug, Eli Lilly and company’s Adcirca.  Mylan Pharmaceuticals received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) and was awarded 180 days of

Mylan offers generic Angiomax injection

Mylan offers generic Angiomax injection

HERTFORDSHIRE, England and PITTSBURGH — Mylan N.V. announced the U.S. launch of bivalirudin for injection, 250 mg single-dose vial, a generic version of Angiomax from The Medicines Company. The product is a direct thrombin inhibitor indicated for use as an anticoagulant in patients. Mylan is offering bivalirudin for injection, 250 mg single-dose vial, to its hospital